FILE PHOTO: The ultrastructural morphology exhibited by the 2019 Novel Coronavirus (2019-nCoV), which was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China, is seen in an illustration released by the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, U.S. January 29, 2020. Alissa Eckert, MS; Dan Higgins, MAM/CDC/Handout via REUTERS.
SINGAPORE (Reuters) - Singapore's Tychan, a biotechnology firm backed by state investor Temasek Holdings, said it will begin human clinical trials next week for a potential monoclonal antibody treatment for COVID-19.
The first phase of the trial to be conducted on 23 healthy volunteers will take about six weeks to evaluate the safety and tolerability of TY027 - a monoclonal antibody that specifically targets SARS-CoV-2, the virus that causes COVID-19.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
